BioBlog ASCO Recap Edition
This online article from MarketWatch outlines the “safety concerns and issues of price hang above the promising immuno-oncology combination trials”.
In this article from Stat, we learn of an initiative in which “a health plan may get an extra discount from a drug maker if a medicine does not help patients as much as expected, or a drug maker may get a credit toward a rebate provided to a health plan”.
ASCO post reports on the results of a study indicating, “women who became pregnant after an early breast cancer diagnosis, including those with estrogen receptor–positive tumors, did not have a higher chance of cancer recurrence and death than those who did not become pregnant”.
Global Study Sets New Risk-Based Standard to Personalise Chemotherapy for Colon Cancer After Surgery
After surgery for lymph-node positive colon cancer (stage III), some patients may only need half of the long-standing standard course of chemotherapy.
The Wall Street Journal reports that, “spending on Medicare’s drug program has soared, growing faster than all other areas of Medicare”.
Abiraterone stops production of testosterone throughout the body by blocking an enzyme that converts other hormones to testosterone.
“While it’s still early, these data are a strong sign that CAR T-cell therapy can send multiple myeloma into remission,” said ASCO Expert Michael S. Sabel, MD, FACS. “It’s rare to see such high response rates, especially for a hard-to-treat cancer. This serves as proof that immunotherapy and precision medicine research pays off. We hope that future research builds on this success in multiple myeloma and other cancers.”
The company cited uncertainty as a reason why it’s exiting the exchanges in all of the state’s counties, particularly the question of whether or not the Trump administration will continue payments to insurers that compensate them for reducing out-of-pocket costs for lower-income enrollees.
The Health, Education, Labor and Pensions committee stated, “The long-awaited hearing will focus on “the process of moving prescription drugs from the manufacturer to patients and how the drug deli system affects what patients pay when picking up their prescriptions.”
HealthDay reports that, “SWOG, the clinical trials network funded by the U.S. National Cancer Institute (NCI), has involved more than 200,000 patient volunteers. These trials have led to approval of 14 new cancer drugs and more than 100 changes to cancer care standards”.